droplet digital PCR
Bio-Rad Q3 Revenues Jump 15 Percent
Bio-Rad's year-over-year Q3 revenue increase was driven primary by sales of PCR and Droplet Digital PCR products due to the COVID-19 pandemic.
Biodesix Prices $72M IPO
Shares of the Boulder, Colorado-based firm will begin trading on the Nasdaq today under ticker symbol "BDSX" at $18 per share.
Bio-Rad Q2 Revenues Fall 6 Percent on COVID-19 Impact
The overall revenue decrease was buoyed by 19 percent year-over-year growth in Life Science segment revenues due to strong PCR-related sales.
Bio-Rad Laboratories Gets FDA Emergency Use Authorization for ddPCR COVID-19 Assay
The triplex assay can be used on the firm's QX200 or QXDx Droplet Digital PCR systems to process 93 patient samples per run.
Multi-Analyte Liquid Biopsy Panel May Aid in Pancreatic Cancer Detection, Staging
The panel's developers at UPenn hope to validate and commercialize a non-invasive assay through a startup called Chip Diagnostics.
Feb 10, 2020
Aug 1, 2019
Bio-Rad Q2 Revenues Down 1 Percent
May 8, 2019
Bio-Rad Laboratories Reports Flat Q1 Revenues
Feb 28, 2019
Bio-Rad Q4 Revenues Down 1 Percent, Beat Estimates
Feb 22, 2019
Oct 25, 2018
Aug 7, 2018
Bio-Rad Q2 Revenues Jump 14 Percent
May 8, 2018
Bio-Rad Q1 Revenues Rise 10 Percent
Nov 17, 2017
Nov 2, 2017
Bio-Rad Q3 Revenues Grow 5 Percent
Oct 16, 2017
Sep 26, 2017